|
Oncogenes and Tumor Suppressors
Citations 261-270 of 795 total displayed.
|
Past content
(since May 2000):
|
Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy
- Jaspal Kaeda, Derville O'Shea, Richard M. Szydlo, Eduardo Olavarria, Francesco Dazzi, David Marin, Susan Saunders, Jamshid S. Khorashad, Nicholas C. P. Cross, John M. Goldman, and Jane F. Apperley
Blood 2006; 107: 4171-4176.
[Abstract]
[Full text]
[PDF]
Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study
- Roberto Cairoli, Alessandro Beghini, Giovanni Grillo, Gianpaolo Nadali, Francesca Elice, Carla Barbara Ripamonti, Patrizia Colapietro, Michele Nichelatti, Laura Pezzetti, Monia Lunghi, Antonio Cuneo, Assunta Viola, Felicetto Ferrara, Mario Lazzarino, Francesco Rodeghiero, Giovanni Pizzolo, Lidia Larizza, and Enrica Morra
Blood 2006; 107: 3463-3468.
[Abstract]
[Full text]
[PDF]
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders
- Francesco Passamonti, Elisa Rumi, Daniela Pietra, Matteo G. Della Porta, Emanuela Boveri, Cristiana Pascutto, Laura Vanelli, Luca Arcaini, Sara Burcheri, Luca Malcovati, Mario Lazzarino, and Mario Cazzola
Blood 2006; 107: 3676-3682.
[Abstract]
[Full text]
[PDF]
Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPAR / ligand TZD18
- Hongyu Liu, Chuanbing Zang, Martin H. Fenner, Dachuan Liu, Kurt Possinger, H. Phillip Koeffler, and Elena Elstner
Blood 2006; 107: 3683-3692.
[Abstract]
[Full text]
[PDF]
Induction of the plasminogen activator inhibitor-2 in cells expressing the ZNF198/FGFR1 fusion kinase that is involved in atypical myeloproliferative disease
- Chitta S. Kasyapa, Padmaja Kunapuli, Lesleyann Hawthorn, and John K. Cowell
Blood 2006; 107: 3693-3699.
[Abstract]
[Full text]
[PDF]
Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML
- Carola Reindl, Ksenia Bagrintseva, Sridhar Vempati, Susanne Schnittger, Joachim W. Ellwart, Katja Wenig, Karl-Peter Hopfner, Wolfgang Hiddemann, and Karsten Spiekermann
Blood 2006; 107: 3700-3707.
[Abstract]
[Full text]
[PDF]
Coexistence of multiple mechanisms of PT523 resistance in human leukemia cells harboring 3 reduced folate carrier alleles: transcriptional silencing, inactivating mutations, and allele loss
- Yotam Kaufman, Ilan Ifergan, Lilah Rothem, Gerrit Jansen, and Yehuda G. Assaraf
Blood 2006; 107: 3288-3294.
[Abstract]
[Full text]
[PDF]
AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1
- Sumiyuki Nishida, Naoki Hosen, Toshiaki Shirakata, Keisuke Kanato, Masashi Yanagihara, Shin-ichi Nakatsuka, Yoshihiko Hoshida, Tsutomu Nakazawa, Yukie Harada, Naoya Tatsumi, Akihiro Tsuboi, Manabu Kawakami, Yoshihiro Oka, Yusuke Oji, Katsuyuki Aozasa, Ichiro Kawase, and Haruo Sugiyama
Blood 2006; 107: 3303-3312.
[Abstract]
[Full text]
[PDF]
Identification of a gene on chromosome 12q22 uniquely overexpressed in chronic lymphocytic leukemia
- Anne Mette Buhl, Jesper Jurlander, Flemming S. Jørgensen, Anne Marie Ottesen, Jack B. Cowland, Lise Mette Gjerdrum, Brian V. Hansen, and Henrik Leffers
Blood 2006; 107: 2904-2911.
[Abstract]
[Full text]
[PDF]
Recent insights into the role of Notch signaling in tumorigenesis
- Kevin G. Leong and Aly Karsan
Blood 2006; 107: 2223-2233.
[Abstract]
[Full text]
[PDF]
|
|
